VMD vs. CO, NAUT, RANI, NLTX, MGTX, SBTX, BVS, CLOV, AVIR, and GUTS
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include Global Cord Blood (CO), Nautilus Biotechnology (NAUT), Rani Therapeutics (RANI), Neoleukin Therapeutics (NLTX), MeiraGTx (MGTX), Silverback Therapeutics (SBTX), Bioventus (BVS), Clover Health Investments (CLOV), Atea Pharmaceuticals (AVIR), and Fractyl Health (GUTS). These companies are all part of the "medical" sector.
Global Cord Blood (NYSE:CO) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viemed Healthcare had 4 more articles in the media than Global Cord Blood. MarketBeat recorded 9 mentions for Viemed Healthcare and 5 mentions for Global Cord Blood. Global Cord Blood's average media sentiment score of 0.23 beat Viemed Healthcare's score of 0.08 indicating that Viemed Healthcare is being referred to more favorably in the news media.
Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
Global Cord Blood received 338 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 74.40% of users gave Global Cord Blood an outperform vote while only 33.33% of users gave Viemed Healthcare an outperform vote.
74.2% of Viemed Healthcare shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 19.2% of Viemed Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Viemed Healthcare has a net margin of 5.32% compared to Viemed Healthcare's net margin of 0.00%. Global Cord Blood's return on equity of 9.47% beat Viemed Healthcare's return on equity.
Summary
Viemed Healthcare beats Global Cord Blood on 10 of the 15 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
